Reprogramming the Epigenome With Vitamin C

Frontiers in Cell and Developmental Biology
Taylor Lee ChongLuisa Cimmino

Abstract

The erasure of epigenetic modifications across the genome of somatic cells is an essential requirement during their reprogramming into induced pluripotent stem cells (iPSCs). Vitamin C plays a pivotal role in remodeling the epigenome by enhancing the activity of Jumonji-C domain-containing histone demethylases (JHDMs) and the ten-eleven translocation (TET) proteins. By maintaining differentiation plasticity in culture, vitamin C also improves the quality of tissue specific stem cells derived from iPSCs that are highly sought after for use in regenerative medicine. The ability of vitamin C to potentiate the activity of histone and DNA demethylating enzymes also has clinical application in the treatment of cancer. Vitamin C deficiency has been widely reported in cancer patients and has recently been shown to accelerate cancer progression in disease models. Therapies involving high-dose vitamin C administration are currently gaining traction in the treatment of epigenetic dysregulation, by targeting aberrant histone and DNA methylation patterns associated with cancer progression.

References

May 31, 1982·Biochemical and Biophysical Research Communications·S Tajima, S R Pinnell
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LevineL R Cantilena
Feb 12, 1998·The Journal of Clinical Investigation·D B AgusD W Golde
Aug 24, 1999·Cell·G L Semenza
Mar 24, 2004·Molecular Cancer·Cathie GarnisWan L Lam
Apr 8, 2004·Annals of Internal Medicine·Sebastian J PadayattyMark Levine
Nov 3, 2004·The Journal of Clinical Investigation·Janakiraman KrishnamurthyNorman E Sharpless
Feb 5, 2005·Palliative Medicine·Catriona R MaylandKeith Allan
Jul 11, 2006·The Journal of Clinical Investigation·Joseph M SavittTed M Dawson
Sep 21, 2006·Nature Reviews. Genetics·Robert J KloseYi Zhang
Mar 24, 2007·Experimental Hematology·Richard K ShadduckHaifaa Abdulhaq
May 8, 2007·Cell·Brian Keith, M Celeste Simon
Nov 22, 2007·Science·Junying YuJames A Thomson
Apr 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Marius WernigRudolf Jaenisch
Oct 7, 2008·Nature Structural & Molecular Biology·Jin HeYi Zhang
Feb 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Alexandros TzatsosPhilip N Tsichlis
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Jun 2, 2009·Nature Genetics·Saskia M C LangemeijerJoop H Jansen
Jun 11, 2009·British Journal of Pharmacology·J MandlG Bánhegyi
Aug 12, 2009·Nature·Han LiManuel Serrano
Aug 22, 2009·Genes & Development·Ana BanitoJesús Gil
Sep 1, 2009·Cell Stem Cell·Yoshinori YoshidaShinya Yamanaka
Oct 3, 2009·Haematologica·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 18, 2009·Expert Review of Anticancer Therapy·Fabio P S SantosFarhad Ravandi
Dec 29, 2009·Cell Stem Cell·Miguel Angel EstebanDuanqing Pei
Jul 21, 2010·Nature·K KimG Q Daley

❮ Previous
Next ❯

Citations

Feb 6, 2020·Critical Reviews in Food Science and Nutrition·Suza Mohammad NurMohammad Imran Khan
Nov 16, 2019·Stem Cell Research & Therapy·Zili LiChengliang Xiong
Jan 26, 2020·Nutrients·Markos G KashiourisAlpha A Fowler
Jan 18, 2020·Biomolecules·Noothan Jyothi SatheeshDietrich Büsselberg
Jul 24, 2020·Cellular & Molecular Immunology·Dieter KabelitzShirin Kalyan
Aug 6, 2020·Journal for Immunotherapy of Cancer·Kirsty TaylorDaniel D De Carvalho
Jun 10, 2020·Cellular & Molecular Biology Letters·Magdalena Przybyło, Marek Langner
Mar 14, 2020·Journal of Applied Toxicology : JAT·Thelma Pavesi, Josino Costa Moreira
Nov 5, 2019·Cellular and Molecular Life Sciences : CMLS·Carlos Godoy-ParejoGuokai Chen
Jan 9, 2021·International Journal of Biological Macromolecules·Ning SunRutao Liu
Nov 22, 2020·International Journal of Molecular Sciences·Felipe ArroyaveFernando Lizcano
Jan 24, 2021·International Journal of Biological Macromolecules·Zhuo HanZekun Guo
Mar 7, 2021·Nutrients·Martin Doseděl On Behalf Of The Oemonom
May 1, 2021·International Journal of Molecular Sciences·Agnieszka Siomek-GoreckaDamian Czarnecki
May 15, 2021·Cell & Bioscience·Tianyuan Shi, Martin Cheung
May 22, 2021·Frontiers in Genetics·John P BrabsonLuisa Cimmino
Jun 3, 2021·International Journal of Molecular Sciences·Deirdra VenneyKen I Mills
Jul 5, 2021·Cell Communication and Signaling : CCS·Yuanjie DingMaryam Farzaneh
Aug 21, 2021·Proceedings of the National Academy of Sciences of the United States of America·Maike BensbergColm E Nestor
Aug 17, 2021·Current Stem Cell Reports·Huajun HanRobert S Chapkin
Nov 4, 2021·Histochemistry and Cell Biology·Douglas J Taatjes, Jürgen Roth
Nov 26, 2021·Immunological Reviews·Heng-Yi ChenChan-Wang Jerry Lio

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
histone acetylation

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.